Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.

Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.

http://www.wikidata.org/entity/Q34290041

about

Individualization of antiretroviral therapy--pharmacogenomic aspect Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics Role of raltegravir in HIV-1 management.Liver hypertrophy: a review of adaptive (adverse and non-adverse) changes--conclusions from the 3rd International ESTP Expert Workshop.Integrase strand transfer inhibitors in the management of HIV-positive individuals.Dosing antiretroviral medication when crossing time zones: a review.Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers.Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.Variability of raltegravir plasma levels in the clinical setting.Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients.

P2860

Q28070574-C2F6CA71-A432-4AA0-ADD5-718732AF7581 Q28553066-5CA18EDE-8257-4B9D-8CF4-4338E560DFA3 Q33585344-30317724-7F01-442E-8C20-F670CF433253 Q35867491-EC84FCDD-E837-4A88-87D1-B5CC38A7A168 Q36018556-BAC8A7AC-5D1F-4A31-AEBB-1D0816C5FEDF Q37273923-F478D276-A7F0-4236-8209-6E807411A02B Q37551700-1059DC7C-9A94-4E09-910C-6BEAF10F7E6F Q38002011-592AAF9C-34DD-48BC-B0DF-0992A1386943 Q38020789-7D8CEF49-01B5-4CD6-B43C-5C6F00C8461D Q38192022-5247DFF6-4615-4C9C-B0F9-333BDBED734B Q38674015-87894767-3296-4B68-ABD2-2DD76A5351F3 Q41686008-AD49018A-6E44-417C-874E-02707AD21C5B Q41736369-FDAC01E8-FFBA-4F90-9755-2E47ADB48DCF Q42253719-BB3A54BD-5002-4664-A5BC-B9FEB7E34719 Q54216681-82530714-4FFF-42AC-A650-F6F87D6D8FF4

P2860

Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.

http://www.wikidata.org/entity/Q34290041

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Pharmacokinetics and pharmacog ...... zanavir in healthy volunteers.

@ast

Pharmacokinetics and pharmacog ...... zanavir in healthy volunteers.

@en

Pharmacokinetics and pharmacog ...... zanavir in healthy volunteers.

@nl

type

label

Pharmacokinetics and pharmacog ...... zanavir in healthy volunteers.

@ast

Pharmacokinetics and pharmacog ...... zanavir in healthy volunteers.

@en

Pharmacokinetics and pharmacog ...... zanavir in healthy volunteers.

@nl

prefLabel

Pharmacokinetics and pharmacog ...... zanavir in healthy volunteers.

@ast

Pharmacokinetics and pharmacog ...... zanavir in healthy volunteers.

@en

Pharmacokinetics and pharmacog ...... zanavir in healthy volunteers.

@nl

P1433

Q34290041-25DE1B0E-0029-4E2A-93EE-A7C1942CA7E7

P1476

Q34290041-3CA71062-01EB-477E-9D93-CB944470C2A7

P2093

Q34290041-0379856F-983D-49E3-BE36-4DB452C675B8

Q34290041-0BF7E472-9F3B-4363-BF63-74A846B6EDC2

Q34290041-19DAB9F5-781E-47B7-B8B6-E4EF5E2A273F

Q34290041-2678AAD8-250C-42D2-8E53-71950CD491CA

Q34290041-6DDCC571-4594-45C3-9176-3C6EB6228912

Q34290041-AB74370F-C3E1-4F13-829F-4411A3A82110

Q34290041-B6197559-B2DF-46E6-A2A5-D7B89CB1E964

Q34290041-F3D234AA-F91C-4B4B-98BD-1642301DDC65

P2860

Q34290041-1CDDB120-DFBB-4C7B-9CC3-0B35228DE422

Q34290041-1D16135B-FB39-4E24-A8BC-9367817EF88F

Q34290041-3F1B02EB-A5E5-4BEF-9972-4276F9411398

Q34290041-6041AF7B-BF29-4EE6-8517-F406A0AF7978

Q34290041-66D927D1-D800-456A-A835-1D39C7880C93

Q34290041-8EEF2CE8-C176-431C-B9B4-929660584DC6

Q34290041-96DA3B33-0A32-46DC-A7C0-DE6E35C4A9E4

Q34290041-9F62BAD0-D5B7-481B-B268-F2D4FEA4AFCC

Q34290041-DC8EA3E8-F5D9-46BF-9FB7-18C6E428E7DB

Q34290041-E0E4370B-5E83-4849-8E87-E113A2BC9E4B

P304

Q34290041-8AADF73D-0325-49BC-912D-D305903465C8

P31

Q34290041-F92323BF-875C-4874-B81C-52A9C6B5E3BD

P356

Q34290041-53314167-F133-4F84-9E74-FB67C0D19662

P407

Q34290041-A2D18953-DE6C-40EE-AB7A-088AF165E487

P433

Q34290041-693783A9-B2D8-4D17-8B31-1B274DFB5CF1

P478

Q34290041-B3811E9D-E326-4B40-96FD-83DDF2C58164

P50

Q34290041-14CC0DBD-D5A0-4015-97F5-B4D0A5964181

Q34290041-754BF93B-0CD1-4B50-923C-C502122AAF15

P577

Q34290041-B0CE25C4-F5DF-4E21-96D8-AFB376B67843

P698

Q34290041-9FBB97FE-A5DF-4DED-940B-0D1AE3EB3BBA

P921

Q34290041-72AE960F-29D0-4FEE-A7DB-1A1EA42C7CE6

P932

Q34290041-26720777-5330-43FF-A6A5-31DC038DDB7C

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics and pharmacog ...... azanavir in healthy volunteers

@en

P2093

Alexandra Calmy

http://www.w3.org/2001/XMLSchema#string

Ashley Margol

http://www.w3.org/2001/XMLSchema#string

Aurélie Fayet

http://www.w3.org/2001/XMLSchema#string

Janice Soo Fern Lee

http://www.w3.org/2001/XMLSchema#string

Julia di Iulio

http://www.w3.org/2001/XMLSchema#string

Meera Kanani

http://www.w3.org/2001/XMLSchema#string

Michael Neely

http://www.w3.org/2001/XMLSchema#string

Roger Jelliffe

http://www.w3.org/2001/XMLSchema#string

P2860

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome.

Induction effects of ritonavir: implications for drug interactions.

Emerging pharmacology: inhibitors of human immunodeficiency virus integration.

Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans.

Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American.

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.

P304

4619-4625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00712-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Tido von Schoen-Angerer

Laurent Arthur Decosterd

P577

2010-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20823282

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

2976128

http://www.w3.org/2001/XMLSchema#string